UK launches fund for commercial manufacture of advanced therapies

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Xur82)
(Image: Getty/Xur82)

Related tags: Uk, UK Biotech

UK government invests further in businesses manufacturing advanced therapies, opening a fund for companies working on technology to improve commercial production.

The new fund will make £3.7m ($4.4m) available to companies that are developing new technology to aid in the commercial production of advanced therapies, including gene therapy and engineered tissue or cell therapy.

The businesses eligible for investment must use external technology to ‘improve process mechanization’ that will support newly developed advanced therapies. In order for a project to be considered for funding, the technology must demonstrate how it will “increase productivity, competitiveness, capability or growth.”

This investment is part of a wider £181m investment by the UK government’s Industrial Strategy Challenge Fund (ISCF) Leading-edge Healthcare Challenge that aims to accelerate the development of advanced therapies.

The overall investment is focused on four areas: digital health technology, advanced therapies treatment centers, viral vector production and medicine manufacturing funding, with the latter being the umbrella under which this most recent funding is included.

The UK government’s funding for advanced therapies comes as the country’s biotech scene is experiencing a boom, with investment rising year-on-year​.

With an increased focus on advanced therapies, such as cell and gene therapies, this has seen a corresponding push for the UK sector to increase its capabilities – particularly in regard to manufacturing.

In a recent report, UK government-funded Cell and Gene Therapy Catapult revealed that employment in production of such therapies increased by 30% between 2017 and 2018​.

Related news

Show more

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

Take the Right Path Upstream with MilliporeSigma | 12-May-2020 | Technical / White Paper

The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Related suppliers

Follow us


View more